Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2012 | 11:25pm CET

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
William.Coote@taro.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TARO PHARMACEUTICAL INDUST
12/02 TARO The Law Offices of Vincent Wong Reminds Investors of a Class Action Invo..
12/02 TARO PHARMACEUTICAL INDUSTRIES : Announces Appointment of Interim CEO
12/01 TARO PHARMACEUTICAL INDUSTRIES : Announces New $250 Million Share Repurchase Aut..
12/01 TARO PHARMACEUTICAL INDUSTRIES : Announces Appointment of Interim CEO
12/01 TARO PHARMACEUTICAL INDUSTRIES : Announces Appointment of New CEO and New Board ..
11/29 TARO PHARMACEUTICAL INDUSTRIES LTD. : Important Deadline Reminder For Taro Pharm..
11/28 Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries ..
11/28 TARO PHARMACEUTICAL INDUSTRIES LTD. : SHAREHOLDER ALERT - Bronstein, Gewirtz & G..
11/26 TARO SHAREHOLDER ALERT BY FORMER LOU : KAHN SWICK & FOTI, LLC REMINDS INVESTORS ..
11/25 DEADLINE ALERT : Brower Piven Alerts Shareholders Of Approaching Deadline In Cla..
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/01 GREENBLATT WIZARDRY : A Quantitative Look At The Magic Formula
11/22 New chief at Taro Pharma
11/09 Taro Pharmaceutical Industries' (TARO) CEO, Kal Sundaram on Q2 2017 Results -..
11/08 Taro Pharmaceutical reports Q3 results
10/28 Indian Pharma Names May Come Under Stress
Advertisement
Financials ($)
Sales 2017 902 M
EBIT 2017 550 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 9,43
P/E ratio 2018 10,34
Capi. / Sales 2017 4,72x
Capi. / Sales 2018 5,08x
Capitalization 4 258 M
More Financials
Chart TARO PHARMACEUTICAL INDUST
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Full-screen chart
Technical analysis trends TARO PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 135 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kal Sundaram Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TARO PHARMACEUTICAL IN..-35.10%4 116
JOHNSON & JOHNSON9.00%303 013
PFIZER INC.-2.01%190 910
ROCHE HOLDING LTD.-19.61%189 262
NOVARTIS AG-19.07%177 818
MERCK & CO., INC.15.85%167 524
More Results